# OnCo record brca-palb2-pdac (cancer). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/cancers/brca-palb2-pdac/>
  a schema:MedicalCondition ;
  onco:kind "cancer" ;
  schema:identifier "brca-palb2-pdac" ;
  schema:name "BRCA or PALB2-mutant pancreatic ductal adenocarcinoma"@en ;
  schema:alternateName "BRCA-mutated pancreatic cancer"@en, "gBRCA pancreatic cancer"@en, "Homologous recombination deficient pancreatic cancer"@en, "PALB2-mutant pancreatic cancer"@en ;
  schema:description "BRCA or PALB2-mutant pancreatic cancer is pancreatic cancer in someone who inherited a faulty copy of a gene that repairs broken DNA. These tumours respond better to platinum chemotherapy, and the POLO trial showed that the PARP inhibitor olaparib, taken after platinum has held the disease, delays its return; that made it the first targeted drug approved for a pancreatic cancer subgroup."@en ;
  schema:url <https://onco.cc/cancers/brca-palb2-pdac/> ;
  schema:dateModified "2026-09-18"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/BRCA_mutation> ;
  schema:citation <https://en.wikipedia.org/wiki/BRCA_mutation>, <https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1455> ;
  onco:tag "subtype-page", "gastrointestinal" ;
  onco:related <https://onco.cc/cancers/metastatic-pdac/>, <https://onco.cc/cancers/resectable-pdac/>, <https://onco.cc/cancers/kras-g12c-pdac/>, <https://onco.cc/cancers/kras-wild-type-pdac/>, <https://onco.cc/cancers/msi-high-pdac/>, <https://onco.cc/cancers/borderline-resectable-pdac/>, <https://onco.cc/cancers/platinum-sensitive-ovarian-cancer/> ;
  onco:technologies <https://onco.cc/technologies/parp-inhibitor/>, <https://onco.cc/technologies/germline-testing/>, <https://onco.cc/technologies/cytotoxic-chemotherapy/>, <https://onco.cc/technologies/pancreatic-surveillance/>, <https://onco.cc/technologies/liquid-biopsy/>, <https://onco.cc/technologies/checkpoint-inhibitor/> ;
  onco:targets <https://onco.cc/targets/brca/>, <https://onco.cc/targets/kras/> ;
  onco:drugs <https://onco.cc/drugs/olaparib/>, <https://onco.cc/drugs/rucaparib/>, <https://onco.cc/drugs/niraparib/>, <https://onco.cc/drugs/talazoparib/>, <https://onco.cc/drugs/folfirinox/>, <https://onco.cc/drugs/nalirifox/>, <https://onco.cc/drugs/gemcitabine-cisplatin/>, <https://onco.cc/drugs/cisplatin/>, <https://onco.cc/drugs/gemcitabine-nab-paclitaxel/>, <https://onco.cc/drugs/ipilimumab/>, <https://onco.cc/drugs/daraxonrasib/> ;
  onco:companies <https://onco.cc/companies/astrazeneca/>, <https://onco.cc/companies/merck/>, <https://onco.cc/companies/pfizer/> ;
  onco:pathways <https://onco.cc/pathways/ddr/>, <https://onco.cc/pathways/homologous-recombination-repair/>, <https://onco.cc/pathways/synthetic-lethality-map/>, <https://onco.cc/pathways/pancreatic-cancer-signalling/> ;
  onco:terms <https://onco.cc/terms/gbrca-mutation/>, <https://onco.cc/terms/hrd/>, <https://onco.cc/terms/platinum-sensitivity/>, <https://onco.cc/terms/brca-reversion-mutations/>, <https://onco.cc/terms/germline-vs-somatic/>, <https://onco.cc/terms/resistance/> ;
  onco:trials <https://onco.cc/trials/polo/>, <https://onco.cc/trials/prodige-24/>, <https://onco.cc/trials/preopanc/>, <https://onco.cc/trials/nct07491445/> ;
  onco:people <https://onco.cc/people/talia-golan/>, <https://onco.cc/people/susan-domchek/>, <https://onco.cc/people/eileen-oreilly/>, <https://onco.cc/people/diane-simeone/>, <https://onco.cc/people/bert-vogelstein/> ;
  onco:pipeline <https://onco.cc/drugs/rucaparib/>, <https://onco.cc/drugs/niraparib/>, <https://onco.cc/drugs/talazoparib/>, <https://onco.cc/drugs/ipilimumab/>, <https://onco.cc/trials/nct07491445/>, <https://onco.cc/ideas/idea-prev-reflex-germline-testing/>, <https://onco.cc/technologies/pancreatic-surveillance/> ;
  onco:standardOfCare <https://onco.cc/technologies/germline-testing/>, <https://onco.cc/terms/gbrca-mutation/>, <https://onco.cc/terms/germline-vs-somatic/>, <https://onco.cc/technologies/pancreatic-surveillance/>, <https://onco.cc/drugs/folfirinox/>, <https://onco.cc/drugs/nalirifox/>, <https://onco.cc/drugs/gemcitabine-cisplatin/>, <https://onco.cc/drugs/cisplatin/>, <https://onco.cc/terms/platinum-sensitivity/>, <https://onco.cc/drugs/olaparib/>, <https://onco.cc/trials/polo/>, <https://onco.cc/drugs/rucaparib/>, <https://onco.cc/technologies/parp-inhibitor/>, <https://onco.cc/drugs/folfirinox/>, <https://onco.cc/trials/prodige-24/>, <https://onco.cc/trials/preopanc/>, <https://onco.cc/terms/neoadjuvant-adjuvant/>, <https://onco.cc/drugs/gemcitabine-nab-paclitaxel/>, <https://onco.cc/drugs/daraxonrasib/>, <https://onco.cc/terms/brca-reversion-mutations/> .